Streetbeat News

Stock Prices

HCAT

Health Catalyst (NASDAQ:HCAT) received mixed analyst ratings over the past three months, with 4 somewhat bullish and 2 indifferent ratings. The average 12-month price target is $10.83, down from $12.33, with a high estimate of $12.00 and a low of $8.00. Analysts from Evercore ISI Group, Piper Sandler, JP Morgan, Stifel, and RBC Capital have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Health Catalyst's financial performance shows a revenue growth rate of 7.93%, a net margin of -29.86%, an ROE of -5.71%, an ROA of -3.07%, and a debt-to-equity ratio of 0.65.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 4:00 pm

CHTR

Charter Communications (NASDAQ:CHTR) is evaluated against its competitors in the Media industry. It has a lower P/E ratio, suggesting growth potential, but a higher P/B ratio, indicating it may be overvalued in terms of book value. Its P/S ratio is below the industry average, suggesting it could be undervalued based on sales. CHTR has a higher ROE and EBITDA than the industry average, showing efficient use of equity and strong profitability. However, its gross profit is below the industry average, and it has a high debt-to-equity ratio, which could indicate financial risk.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 4:00 pm

CDW

CDW Corp (NASDAQ:CDW) is evaluated against competitors in the Electronic Equipment, Instruments & Components industry. CDW trades at a premium with a P/E of 27.55, P/B of 16.33, and P/S of 1.38, all above industry averages. The company's ROE at 18.43% and higher EBITDA and gross profit indicate strong profitability, despite a revenue decline of -9.45%. CDW's high debt-to-equity ratio of 3.24 suggests increased financial risk.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 4:00 pm

LLY

Eli Lilly (NYSE:LLY) has delivered an average annual return of 11.54% over the past 20 years, outperforming the market by 4.17% annually. A $1000 investment in LLY 20 years ago would be worth $9,041.95 today. Eli Lilly currently has a market cap of $580.10 billion.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 4:00 pm

BNTX

A comparative study evaluates BioNTech (NASDAQ:BNTX) against its biotechnology industry competitors, analyzing financial metrics and market position. BioNTech's low P/E, P/B, and P/S ratios suggest undervaluation, but its ROE, EBITDA, gross profit, and revenue growth are below industry averages, indicating potential financial weaknesses. The company's low debt-to-equity ratio is favorable, suggesting a strong financial position with less reliance on debt.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 4:00 pm

PANW

Over the past 10 years, Palo Alto Networks (NASDAQ:PANW) has significantly outperformed the market, with an average annual return of 30.56%. A $100 investment in PANW a decade ago would be worth $1,492.82 today. The company's market capitalization currently stands at $89.76 billion.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 4:00 pm

NYCB

Wedbush analyst David Chiaverini has upgraded New York Community (NYSE:NYCB) from Underperform to Neutral and set a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 3:59 pm

ENB

EPD

MO

The article highlights three high-yield dividend stocks - Enbridge Inc (ENB), Altria Group Inc (MO), and Enterprise Products Partners LP (EPD) - as attractive investment options for 2024 due to their strong fundamentals, growth prospects, and consistent dividend payouts. It emphasizes the importance of these stocks in a diversified portfolio, especially with anticipated rate cuts, and advises investors to conduct thorough research and consult financial advisors.

Portfolio Pulse from Surbhi Jain

January 03, 2024 | 3:59 pm

CBOE

ICE

NDAQ

Fox Business Reporter Eleanor Terrett reports that the SEC is meeting with major exchanges including Nasdaq, CBOE, and NYSE to finalize comments on the 19B-4 forms submitted by issuers of Bitcoin (BTC) spot ETFs.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 3:58 pm

ESPR

Esperion Therapeutics' stock is trading lower following an announcement of a $125 million amendment to its collaboration with Daiichi Sankyo Europe, which also includes a resolution to pending litigation.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 3:54 pm